{"id":978,"date":"2025-12-03T15:03:44","date_gmt":"2025-12-03T14:03:44","guid":{"rendered":"https:\/\/lensounds.com\/science\/ato-101-perseverance-eu-phase1\/"},"modified":"2025-12-03T15:03:44","modified_gmt":"2025-12-03T14:03:44","slug":"ato-101-perseverance-eu-phase1","status":"publish","type":"science","link":"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/","title":{"rendered":"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)"},"content":{"rendered":"

Clinical Trial Information<\/h2>\n

ClinicalTrials.gov ID:<\/strong> NCT07260162<\/p>\n

Sponsor:<\/strong> Institut Cancerologie de l’Ouest<\/p>\n

Official Title:<\/strong> A First In Human Phase I Trial Evaluating Safety, Tolerability and Response of [211At]At-Girentuximab (ATO-101\u2122) in Patients With Non-Muscle-Invasive Bladder Cancer Refractory to Standard Treatment<\/p>\n

Brief Summary<\/h2>\n

Non-Muscle-Invasive Bladder cancer (NMIBC) tumours often recur despite TransUrethral Resection of Bladder (TURB) and Bacillus Calmette-Guerin (BCG) intravesical instillations, and have no effective conservative treatment options. Alpha emitters like Astatine-211 (211At), due to their short path and short half-life, show promise for superficial targets such as NMIBC.<\/p>\n

Carbonic anhydrase IX (CAIX), overexpressed in 70-90% of NMIBC cases but absent in healthy tissues, is an ideal target.<\/p>\n

A clinical feasibility Positron emission tomography-computed tomography (PET\/CT) imaging study was conducted to evaluate the targeting potential of this therapeutic approach.<\/p>\n

Publication Information<\/h2>\n

Date:<\/strong> 3 December 2025<\/p>\n

Source:<\/strong> ClinicalTrials.gov<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

ClinicalTrials.gov ID\u00a0NCT07260162 –
\nSponsor\u00a0Institut Cancerologie de l'Ouest
\n– ClinicalTrials.gov \u2013 NCT07260162<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"science_category":[50],"class_list":["post-978","science","type-science","status-publish","hentry","science_category-ato-101-publications"],"yoast_head":"\nEvaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) - Atonco<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) - Atonco\" \/>\n<meta property=\"og:description\" content=\"ClinicalTrials.gov ID\u00a0NCT07260162 - Sponsor\u00a0Institut Cancerologie de l'Ouest - ClinicalTrials.gov \u2013 NCT07260162\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/ato-101-perseverance-eu-phase1\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/ato-101-perseverance-eu-phase1\\\/\",\"name\":\"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) - Atonco\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"datePublished\":\"2025-12-03T14:03:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/ato-101-perseverance-eu-phase1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/ato-101-perseverance-eu-phase1\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/ato-101-perseverance-eu-phase1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) - Atonco","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/","og_locale":"en_US","og_type":"article","og_title":"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) - Atonco","og_description":"ClinicalTrials.gov ID\u00a0NCT07260162 - Sponsor\u00a0Institut Cancerologie de l'Ouest - ClinicalTrials.gov \u2013 NCT07260162","og_url":"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/","og_site_name":"Atonco","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/","url":"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/","name":"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) - Atonco","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"datePublished":"2025-12-03T14:03:44+00:00","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/science\/ato-101-perseverance-eu-phase1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/atonco-pharma.com\/en\/science\/"},{"@type":"ListItem","position":3,"name":"Evaluation of Safety, Tolerability and Response of ATO-101\u2122 in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science\/978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/science"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=978"}],"wp:term":[{"taxonomy":"science_category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science_category?post=978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}